How to Taper Off Wegovy

Published May 25, 2026Updated May 27, 2026Last reviewed May 25, 2026

For the broader cluster context, see the semaglutide long-term maintenance hub.

Author: HealthRX Editorial Team Medically reviewed by: Dr. Mark Halpern, MD (Internal Medicine, Obesity Medicine) Last clinical review: May 2026

Compounded semaglutide is not FDA-approved. This article is patient education and does not replace consultation with a licensed clinician.

Rachel, 41, in Scottsdale, had been on compounded semaglutide at 2.4 mg for seven months when she decided she wanted to come off. She'd lost 38 pounds. Her A1C had dropped from 5.9 to 5.2. "I thought I was done," she told her prescriber during a telehealth check-in. "Like finishing a course of antibiotics." Her prescriber's response was the same one obesity medicine doctors give dozens of times a week now: this isn't an antibiotic. And the way you stop matters almost as much as the way you started.

This guide covers how to taper off Wegovy (or compounded semaglutide) in practical, clinical terms. There's a short version for straightforward cases and a longer version for the situations that don't fit the standard mold. Both are here.

This guide sits inside the broader Semaglutide Long-Term and Maintenance cluster, which is part of the compounded semaglutide pillar guide.

Why "Just Stopping" Is the Wrong Mental Model

The single most important study for understanding what happens when semaglutide goes away is STEP-4. In that trial, patients completed a 20-week open-label run-in on active drug, then were randomized either to continue at 2.4 mg or switch to placebo. The placebo arm regained roughly two-thirds of the weight they'd lost over the following 48 weeks. The active arm kept losing, modestly.

People read that and think the drug "stops working" once you stop taking it. That's backwards. The correct read is that the underlying biology of weight regulation reasserts itself once the pharmacologic support is removed. Think of it like blood pressure medication: stop taking your ACE inhibitor, and your blood pressure climbs back up. Nobody calls that a failure of the drug. It's the nature of the condition.

This distinction matters for tapering because it reframes the goal. You're not trying to "get off the medication and keep all the weight off," at least not automatically. You're trying to find out whether your maintenance behaviors (the eating patterns, the activity, the sleep) are strong enough to hold ground at progressively lower doses of support.

The Taper Framework, Step by Step

There is no FDA-endorsed taper protocol for Wegovy or semaglutide. What exists is clinical convention, and it's straightforward: reverse the titration schedule.

For a patient at 2.4 mg maintenance, the reference pattern looks like this:

2.4 mg → 1.7 mg for four to eight weeks
1.7 mg → 1.0 mg for four to eight weeks
1.0 mg → 0.5 mg for four to eight weeks
0.5 mg → discontinuation

The pace is adjusted to the individual. At each step-down, the clinician and patient check a short list: Is hunger returning? Is weight stable? How's sleep? Is the patient still hitting their activity and eating targets? The taper is really a structured stress test for maintenance habits under decreasing pharmaceutical coverage.

Here's the thing: patients whose lifestyle infrastructure is solid often navigate the step-downs without dramatic changes. Patients who relied heavily on the appetite suppression and didn't build durable habits during active treatment tend to notice each dose reduction acutely. The taper reveals which camp you're in, and that information is itself valuable.

What You're Actually Feeling (and What You're Not)

There is no defined pharmacologic withdrawal syndrome with semaglutide. You won't get shaky, anxious, or sick the way you might stopping an SSRI abruptly. The molecule clears slowly given its long half-life (about a week), so even after your last injection, meaningful drug levels persist for several weeks.

What patients do notice is the return of appetite signals. The quiet stomach, the indifference to food between meals, the easy portion control: those fade. For many patients, this return of hunger feels like something has gone wrong. It hasn't. It's the normal biology re-emerging.

Some patients also notice the return of food noise, that persistent background hum of thinking about food. Whether that's strictly physiological or partly psychological is debated. Either way, it's real, and it's one of the things a slow taper lets you acclimate to gradually rather than all at once.

Restarting After a Gap

Rachel's prescriber told her something else that's become standard clinical advice: if you stop and later decide to restart, you don't jump back to your old maintenance dose. You re-titrate from a lower step.

Two reasons. First, tolerability. The slow-gastric-emptying effect that causes nausea in the early weeks has to be rebuilt. Jumping to 2.4 mg after months off is a reliable way to spend a weekend miserable. Second, it gives the prescriber a chance to reassess. Your clinical picture may have changed. Your weight, your labs, your other medications, your goals. A restart is a new clinical conversation, not a refill.

The Chronic-Therapy Question

The trial evidence (STEP-1, STEP-3, STEP-4, SELECT, LEADER, SUSTAIN) collectively supports framing semaglutide as a chronic therapy for a chronic condition. That framing is uncomfortable for a lot of patients who came in expecting a defined course: take it for six months, lose the weight, move on.

My genuinely held opinion: the obesity medicine field has done patients a disservice by being vague about this. The honest message should be stated plainly at the start of treatment. Obesity is a chronic metabolic condition. Pharmacotherapy for it is likely long-term, possibly lifelong, just like statins for cholesterol or metformin for diabetes. A taper is reasonable to attempt, and some patients do maintain their losses. But the base rate for sustained maintenance off-drug, based on STEP-4, is not encouraging without continued pharmacologic or structured behavioral support.

That doesn't mean you shouldn't try tapering. It means you should try it with eyes open, with a monitoring plan, and with a clear agreement with your prescriber about what triggers a conversation about resuming treatment.

Four Things Patients Get Wrong About Tapering

"Compounded semaglutide is FDA-approved, just like Wegovy." It is not. Compounded preparations use the same active molecule, and the clinical evidence for that molecule comes from the branded trials. But compounding pharmacies operate under a different regulatory framework (503A or 503B), and compounded semaglutide has not been independently tested in randomized trials at the same scale. The distinction matters.

"If the side effects were bad, the drug wasn't working." STEP-1 and STEP-3 data don't support this. Patients with mild GI symptoms and patients with pronounced nausea both achieved clinically meaningful weight loss. Side effect intensity is not a proxy for efficacy.

"Lifestyle doesn't matter much when you're on the medication." STEP-3, which paired semaglutide with a structured lifestyle intervention, produced greater mean weight loss than STEP-1, which used medication alone. Lifestyle is additive and not optional for durable outcomes, and it's especially not optional if you plan to taper off.

"Stopping the medication resets me to my pre-treatment body." Not exactly. STEP-4 showed partial regain, not complete regain, over 48 weeks after switching to placebo at week 20. The biology trends back toward baseline, but the trajectory depends on what behavioral and metabolic changes you've made during active treatment.

Practical Notes for Compounded Semaglutide Patients

The active ingredient in compounded preparations is the same as in Wegovy and Ozempic. The taper principles are the same. What differs is the supply chain, the regulatory oversight, and sometimes the available dose increments. Compounding pharmacies can sometimes prepare intermediate doses (0.75 mg, for instance) that aren't available in the branded pen, which can actually make a smoother taper possible.

The clinician relationship matters more than the brand of program. A program that supports honest clinical conversation, responds to side effects with appropriate dose adjustments, and provides clear follow-up between refills will produce better outcomes than a slick interface with weak clinical infrastructure behind it.

Adjacent Reading

Where This Fits

This article is part of the Semaglutide Long-Term and Maintenance cluster. For a broader treatment of the molecule, the regulatory pathway, the 503A and 503B compounding framework, and the clinical evidence base, the compounded semaglutide pillar guide is the primary reference on this site.

Frequently Asked Questions

Is tapering off semaglutide necessary?

There is no pharmacologic withdrawal syndrome, so tapering isn't medically required in the way it is for, say, benzodiazepines. But most clinicians recommend it because a gradual step-down lets appetite signals return incrementally and gives you a real-time read on whether your maintenance habits hold up at lower doses.

What happens to weight after stopping?

STEP-4 showed that patients who switched from active drug to placebo at week 20 regained a substantial portion of lost weight over the subsequent 48 weeks. The pattern is consistent with the chronic-condition model of obesity, not a failure of willpower.

Can a patient restart after a long break?

Yes, but restarting after a multi-month gap typically means resuming titration from a lower step rather than jumping directly to the prior maintenance dose. This is for both tolerability and clinical safety.

How long does a full taper take?

For a patient stepping down from 2.4 mg through all four dose levels, a typical taper runs 16 to 32 weeks, depending on how long the clinician holds at each step. There's no penalty for going slower.

Should I change my diet or exercise during the taper?

Ideally you've already built those habits during active treatment. During the taper, maintaining (not increasing) your current lifestyle pattern is the goal. Major changes during a taper make it harder to tell what's causing any weight shifts.

What if I start regaining weight during the taper?

Talk to your prescriber. Regain during a taper is common and is itself clinical information. It may mean holding at the current dose longer, slowing the step-down schedule, or reconsidering whether continued therapy at a maintenance dose is the better long-term plan.

Is there a difference between tapering off branded Wegovy and compounded semaglutide?

The molecule is the same. The taper principles are the same. Compounded preparations may offer more flexible dosing increments, which can be an advantage for a gradual taper. The key difference is regulatory: compounded semaglutide is not FDA-approved and is prepared under a distinct oversight framework.

Compliance and Authorship

This article references the STEP-1, STEP-3, STEP-4, SUSTAIN, SELECT, and LEADER clinical trial programs where appropriate. It is intended as patient education and does not replace consultation with a licensed clinician.